Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
about
Human polyomavirus reactivation: disease pathogenesis and treatment approachesChemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaOfatumumab: a novel monoclonal anti-CD20 antibodyRituximab: mechanism of actionThe emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaMolecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainEradication of melanomas by targeted elimination of a minor subset of tumor cellsCurrent trends in management of hepatitis B virus reactivation in the biologic therapy eraDo self-perpetuating B lymphocytes drive human autoimmune disease?Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapyThe future of biologic agents in the treatment of Sjögren's syndromeTargeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalBiological response modifiers in cancerEnhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasAnti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma TherapyCritical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityrLymphoma Immunotherapy: Current StatusThe evolution within usHepatitis B virus reactivation with rituximab-containing regimenLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsHelicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphomaFrom monoclonal antibodies to chimeric antigen receptors for the treatment of human malignanciesComplement in monoclonal antibody therapy of cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyPolymer-drug conjugates: origins, progress to date and future directionsNovel immunotherapies for hematologic malignanciesBiologics in dermatology: an integrated reviewNew antibody approaches to lymphoma therapyFirst Isolation of West Nile virus from a patient with encephalitis in the United StatesTheranostic applications of antibodies in oncology.Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesLimited Stage Follicular Lymphoma: Current Role of Radiation TherapyHarnessing the Microbiome to Enhance Cancer ImmunotherapyAntibody evolution beyond NatureRemission of cold hemagglutinin disease induced by rituximab therapyStatins impair antitumor effects of rituximab by inducing conformational changes of CD20Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivoIn vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice
P2860
Q21285083-E52CAFDF-B11E-4C9D-B11B-6CFA0BCA5E1DQ24243100-C1BAF9D9-1C67-4A6A-AF8E-4D3A266986A0Q24604065-845E73D6-746E-4200-B7BE-55F4D55C97E9Q24607358-1CBB0E46-FB99-4F6C-A1A3-730FF8DDED8EQ24617708-F66896BA-BB8B-4171-80EE-341273461197Q24619923-5F01047D-D7E5-4822-8040-9A939E82CFB5Q24624761-64F12BAA-3C50-4879-ABEE-35F9373BB3DCQ24634879-4ECD31A5-8259-4AD3-9506-43286AED2B02Q24642957-5D55FEE9-BE9D-4132-BD5B-092FAA252814Q24646477-A9FD6C72-457B-4B52-A00E-649132AB1988Q24681044-4C4CE960-9534-4975-BB54-46204FD3ED90Q24681992-9215F1DE-3F15-4B4A-AEC8-3D0F1880A1ADQ24685049-D314FBA6-AE4B-4AA5-83B4-9D7D76757F79Q24813078-727D4F14-149B-4124-9222-82D7FE85D207Q26749139-49729AF6-E646-4470-BBEA-B54DB67F4313Q26775363-F23FEB3E-0BF1-461F-BB7F-0931EBFDD837Q26775837-4036B8E6-0328-4540-BFF8-92BEE793A280Q26776480-BE6922A8-0AE0-47C8-B861-37B0303ACB59Q26782902-BF59661C-AC71-470F-87DF-5392FC7E6605Q26801603-7115FF27-89C3-4F65-BE63-DE7BF4FE6ECBQ26830484-4AF382A4-504E-4A5E-8B23-1ED3EB46F54CQ26849243-EA3C55A9-232F-4574-B8C1-F3197D3C2268Q26851987-F90157D9-FC29-42F5-B946-EB40836DFE44Q26852919-1A7A2690-7AF1-44E3-A4D9-75BA254E94AEQ26860800-BD966B20-7119-4B9D-BAF9-7535C048F1E3Q26993238-E70AB973-E6A1-4488-9BCC-0D576F4CC8D1Q27002505-C3A59C18-BFA2-4CCB-8A27-6FB38E48EBDBQ27004436-36166AD1-F4A2-400A-81D6-7870562C2260Q27004638-6F2E3AC3-28EE-47AE-8B42-F9F064313F78Q27022373-C6BA68BC-2982-48FA-8BE2-59B7C9A8FDA8Q27489546-5EEFEAC5-EE5D-428B-A547-B8B81C72972AQ27693293-CDDC963B-DDEC-409D-8991-AAF06C6FED9BQ27694769-8ACEC6B8-221B-42C3-B709-F0B43B40353FQ28079742-05AF9FA5-96AF-4CCA-BD31-974137B28DB2Q28088598-F7193211-2FCF-414C-9267-D85C0ED89C4FQ28216171-9B5E4A1D-41B8-4E21-BD42-B21DE6BDE512Q28366177-5AF80BB5-0A81-4005-BE3E-8EE3FFE8632AQ28472420-01D0F2CA-8D01-496A-98BC-92C9117B090CQ28740388-2DF329D3-81EE-4ED6-B95F-0B85C8CAAF26Q28752150-A63C2DE7-8BF4-4737-A9B8-1F602F9D2048
P2860
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Rituximab chimeric anti-CD20 m ...... a four-dose treatment program.
@en
Rituximab chimeric anti-CD20 m ...... a four-dose treatment program.
@nl
type
label
Rituximab chimeric anti-CD20 m ...... a four-dose treatment program.
@en
Rituximab chimeric anti-CD20 m ...... a four-dose treatment program.
@nl
prefLabel
Rituximab chimeric anti-CD20 m ...... a four-dose treatment program.
@en
Rituximab chimeric anti-CD20 m ...... a four-dose treatment program.
@nl
P2093
P1476
Rituximab chimeric anti-CD20 m ...... a four-dose treatment program
@en
P2093
A J Grillo-López
B K Dallaire
F Cabanillas
I Bence-Bruckler
M E Williams
P304
P356
10.1200/JCO.1998.16.8.2825
P407
P50
P577
1998-08-01T00:00:00Z